ROSWELL, Ga., July 25, 2017 /PRNewswire/ -- StimLabs is announcing two revolutionary products in regenerative medicine. Revita®,the first full thickness placental membrane allograft in a shelf-stable format, and Ascent™, an amniotic fluid allograft that captures key amniotic fluid components in a shelf-stable powder. Processed using the patent-pending Clearify™ method, Revita
The Revita Difference
The Ascent Difference
StimLabs was founded in 2015 with a focus on rapid, differentiated product iteration backed by robust scientific and clinical evidence. In pursuit of this goal, StimLabs' first two products leverage the unique capabilities of amniotic tissues. Amniotic tissues and fluids support the fetus throughout gestation and are rich in biological components that direct cellular activity. While these non-controversial tissues are typically discarded, StimLabs is using proprietary processing methods to capture and preserve these unique components in Revita and Ascent.
Future products in the StimLabs pipeline extend beyond placental-derived products to more advanced bioactive medical devices in regenerative medicine. Industry reports indicate that the global regenerative medicine market will expand from $18.9 billion in 2016 to over $53.7 billion by 2021. "Our approach is to rapidly develop and commercialize products that combine the unique benefits of pharmaceuticals, medical devices, and tissue transplants," said John Daniel, Founder and CEO of StimLabs. "To realize this goal, we've hired an exceptional team with over 100 years of experience across tissue engineering, cell biology, wound healing, and medical devices."
StimLabs is currently focusing on the following initiatives:
StimLabs, LLC, was founded in 2015 with a desire to advance the state of regenerative medicine. Within a year of its inception, StimLabs built and certified an ISO Class 7 clean room facility, conceptualized and launched a suite of amniotic-derived products, developed an extensive product pipeline across a range of clinical applications, and established a portfolio of intellectual property. StimLabs portfolio of products includes Ascent™, a shelf-stable injectable amniotic fluid allograft, and Revita®, an intact human placental membrane allograft that preserves all layers of the native tissue in a shelf-stable format. These groundbreaking products apply to a wide range of clinical applications and provide a foundation on which StimLabs is developing new regenerative technologies at the intersection of pharmaceuticals, medical devices, and tissue transplants. For more information, visit www.stimlabs.com.
Contact Chas Harris 1225 Northmeadow Parkway Suite 104 Roswell, GA 30076 firstname.lastname@example.org www.stimlabs.com
1. Schiavo, A. Endothelial properties of third-trimester amniotic fluid stem cells cultured in hypoxia. Stem Cell Res Ther. 2015; 6: 209.
2. Caplan, A. Mesenchymal Stem Cells: Time to Change the Name! Stem Cells Transl Med. 2017 Jun;6(6):1445-1451.
View original content:http://www.prnewswire.com/news-releases/stimlabs-enters-regenerative-medicine-market-with-two-groundbreaking-amniotic-tissue-products-300493787.html
Subscribe to our Free Newsletters!
Necrotizing fasciitis is a rare life threatening bacterial infection of the tissue below the skin ...
Menstruation or period is the discharge of blood and mucus called menses from the uterus via the ...
Chronic dieting is associated with eating disorders that mainly include unhealthy eating practices ...View All